#evaxion risultati di ricerca

Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 $EVAX, #Evaxion crweworld.com/article/news-p…


The Real Numbers Behind Evaxion Biotech Revealed $EVAX, #EvaxionBiotech, #Evaxion crweworld.com/article/news-p…


LucidQuest Updates > Vaccines Weekly Update – October 3rd 2025 dlvr.it/TNRgbG #News #Evaxion #personalizedcancervaccine Comment below!

_timos_'s tweet image. LucidQuest Updates > Vaccines Weekly Update – October 3rd 2025 dlvr.it/TNRgbG #News #Evaxion #personalizedcancervaccine Comment below!

Evaxion to present new data at AACR Annual Meeting $EVAX, #Evaxion crweworld.com/article/news-p…


Recent clinical data confirms significantly improved predictive power of Evaxion 's AI-Immunology platform $EVAX, #Evaxion, #EvaxionBiotech crweworld.com/article/news-p…


Evaxion Biotech reveals new immune data from ongoing phase 2 trial: 80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response $EVAX, #Evaxion, #EvaxionBiotech crweworld.com/article/news-p…


Evaxion Biotech: Phase 1 Dose Escalation Study Data Show 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01 $EVAX, #EvaxionBiotech, #Evaxion crweworld.com/article/news-p…


Evaxion announces business update and third quarter 2025 financial results $EVAX, #Evaxion crweworld.com/article/news-p…


Evaxion expands AI-Immunology platform into autoimmune diseases $EVAX, #Evaxion crweworld.com/article/news-p…


Evaxion: Merck exercises its option on vaccine candidate EVX-B3 for a cash payment of $7.5M $EVAX, #Evaxion, #EvaxionBiotech, $MRK, #Merck, #MSD crweworld.com/article/news-p…


Key Date Approaching for Evaxion Shareholders $EVAX, #Evaxion, #EvaxionBiotech crweworld.com/article/news-p…


Evaxion announces business update and full year 2024 financial results $EVAX, #Evaxion, #EvaxionBiotech crweworld.com/article/news-p…


Evaxion significantly expands vaccine development collaboration with Merck $EVAX, #Evaxion, $MRK, #Merck, #MSD crweworld.com/article/news-p…


Firemný profil EVAXION SK, s.r.o. - firmynaslovensku.sk/evaxion-sk-s-r… #EVAXION #SK, #s.r.o.


Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01 $EVAX, #Evaxion, #EvaxionBiotech crweworld.com/article/news-p…


Evaxion: AI-Immunology platform shows 86% vaccine target precision in phase 2 personalized cancer vaccine trial $EVAX, #Evaxion crweworld.com/article/news-p…


New data shows the unique scalability of Evaxion’s AI-Immunology platform in glioblastoma $EVAX, #Evaxion crweworld.com/article/news-p…


Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01 $EVAX, #Evaxion crweworld.com/article/news-p…


Evaxion announces business update and second quarter 2025 financial results $EVAX, #Evaxion, #EvaxionBiotech crweworld.com/article/news-p…


Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025 $EVAX, #Evaxion, #EvaxionBiotech crweworld.com/article/news-p…


Key Date Approaching for Evaxion Shareholders $EVAX, #Evaxion, #EvaxionBiotech crweworld.com/article/news-p…


Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01 $EVAX, #Evaxion, #EvaxionBiotech crweworld.com/article/news-p…


Evaxion Biotech reveals new immune data from ongoing phase 2 trial: 80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response $EVAX, #Evaxion, #EvaxionBiotech crweworld.com/article/news-p…


Evaxion to announce business update and full year 2024 financial results $EVAX, #Evaxion, #EvaxionBiotech crweworld.com/article/news-p…


Evaxion Biotech to reveal new biomarker and immune data from the ongoing phase 2 trial for AI-designed personalized cancer vaccine EVX-01 $EVAX, #Evaxion, #EvaxionBiotech crweworld.com/article/news-p…


Evaxion announces closing of $10.8 million public offering $EVAX, #Evaxion, #EvaxionBiotech crweworld.com/article/news-p…


Evaxion to announce business update and third quarter 2024 financial results $EVAX, #Evaxion, #EvaxionBiotech crweworld.com/article/news-p…


Recent clinical data confirms significantly improved predictive power of Evaxion 's AI-Immunology platform $EVAX, #Evaxion, #EvaxionBiotech crweworld.com/article/news-p…


Evaxion significantly expands vaccine development collaboration with Merck $EVAX, #Evaxion, $MRK, #Merck, #MSD crweworld.com/article/news-p…


Evaxion Biotech: Phase 1 Dose Escalation Study Data Show 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01 $EVAX, #EvaxionBiotech, #Evaxion crweworld.com/article/news-p…


Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology Platform $EVAX, #Evaxion crweworld.com/article/news-p…


The Real Numbers Behind Evaxion Biotech Revealed $EVAX, #EvaxionBiotech, #Evaxion crweworld.com/article/news-p…


Evaxion Announces Increased Focus and Fast-Tracking of its New AI Discovery to Patients zpr.io/NbePcQvT4HM4 #AIDiscovery #EVAXION #ArtificialIntelligence #DataAnalysis #DrugDiscovery

pharminews's tweet image. Evaxion Announces Increased Focus and Fast-Tracking of its New AI Discovery to Patients
zpr.io/NbePcQvT4HM4
#AIDiscovery #EVAXION #ArtificialIntelligence #DataAnalysis #DrugDiscovery

LucidQuest Updates > Vaccines Weekly Update – October 3rd 2025 dlvr.it/TNRgbG #News #Evaxion #personalizedcancervaccine Comment below!

_timos_'s tweet image. LucidQuest Updates > Vaccines Weekly Update – October 3rd 2025 dlvr.it/TNRgbG #News #Evaxion #personalizedcancervaccine Comment below!

@EIB agrees a EUR20 million loan with #Evaxion in Denmark. Together with @EUScienceInnov we support their development of vaccines and cures for infectious diseases based on #Artificialintelligence. Rapidly creating vaccines for new diseases is more important than ever. #IDFF

KettelThomsen's tweet image. @EIB agrees a EUR20 million loan with #Evaxion in Denmark. Together with @EUScienceInnov we support their development of vaccines and cures for infectious diseases based on #Artificialintelligence. Rapidly creating vaccines for new diseases is more important than ever. #IDFF

Biosynth are Proud to Supply Evaxion’s Phase IIb Trial for Personalized Neoantigen Peptide Cancer Vaccines "Proud to contribute to life-improving breakthroughs” Read full blog here...ow.ly/XyKL50LlrwP @Biosynth #Evaxion

BiosynthGroup's tweet image. Biosynth are Proud to Supply Evaxion’s Phase IIb Trial for Personalized Neoantigen Peptide Cancer Vaccines 

"Proud to contribute to life-improving breakthroughs”
 Read full blog here...ow.ly/XyKL50LlrwP

@Biosynth #Evaxion

Loading...

Something went wrong.


Something went wrong.